Caplin Point Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹630 crore and net profit of ₹182 crore for the September 2026 quarter.
Caplin Point Laboratories (NSE: CAPLIPOINT) closed at ₹2,029.10 on 20 Nov 2026, up 5.7% over the past year. Its market capitalisation is ₹15,424 crore and it trades at 22.4 times earnings.
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.